Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Area deprivation index as a predictor of survival and treatment disparities in older adults with Acute Myeloid Leukemia: A population-based Study

Valerie Tran, Gloribel Bonilla, Caroline Mulligan et al. Nov 03, 2025 pp. 2847-2847 10.1182/blood-2025-2847

Abstract Introduction: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with poor prognosis, particularly in older adult...

Dermatologic toxicities associated with talquetamab in patients with Relapsed/Refractory multiple myeloma: A systematic review and meta-analysis

Hosana Candreva, Zaraith Coy, Madhu Bhargavi Chandra et al. Nov 03, 2025 pp. 7581-7581 10.1182/blood-2025-7581

Abstract Introduction Multiple myeloma (MM) is an incurable malignancy, and the management of relapsed/refractory (RR) c...

Hydroxyurea sequesters the histone methyltransferase G9a at stressed replication forks to reactivate fetal hemoglobin

Brian Do, Gillian Oaks, Claire Choplick et al. Nov 03, 2025 pp. 2919-2919 10.1182/blood-2025-2919

Abstract Perturbations to S phase that lead to replication stress can induce clinically relevant changes in cell state, such as differentiat...

Optimal trispecific CAR construct simultaneously targets BCMA, GPRC5D, and CD38 to treat antigen-heterogeneous multiple myeloma

Jincai Zhou, Xinran Luo, Kai Wu et al. Nov 03, 2025 pp. 2292-2292 10.1182/blood-2025-2292

Abstract Introduction: BCMA, GPRC5D, and CD38 are highly and independently expressed on malignant plasma cells in relapsed/refractory multip...

Synthetic oligonucleotides contain synthesis errors that are propagated into the genome by editing through homology-directed repair

Stacia Wyman, Zulema Romero Garcia, Seok-Jin Heo et al. Nov 03, 2025 pp. 4321-4321 10.1182/blood-2025-4321

Abstract Single-stranded oligonucleotides (ssODNs) serve as donor templates for gene editing through targeted endonuclease cleavage and homo...

CD19 CAR-T cell therapy in AML1-ETO positive Acute Myeloid Leukemia: A multi-omics analysis of response determinants

Anqi Zhang, Jie Zhao, Yicheng Zhang et al. Nov 03, 2025 pp. 6957-6957 10.1182/blood-2025-6957

Abstract Background: CD19-directed CAR-T therapy has demonstrated remarkable clinical efficacy in B-cell malignancies, leading to multiple F...

Therapy-related AML (t-AML) on the rise: A national perspective on evolving trends, treatment outcomes, and prognostic implications in hospitalized patients

Prakhyath Srikaram, Pujitha Vallivedu Chennakesavulu, Umesh Bhagat et al. Nov 03, 2025 pp. 5181-5181 10.1182/blood-2025-5181

Abstract Introduction: Therapy-related Acute Myeloid Leukemia (t-AML) is defined as a type of Acute Myeloid Leukemia (AML) that arises from...

Intravital imaging of the spatiotemporal dynamics of fibrinolysis in a murine model of vascular injury

Sarah Tashbook, Tomasz Brzoska Nov 03, 2025 pp. 3059-3059 10.1182/blood-2025-3059

Abstract Fibrinolysis plays a key role in maintaining hemostatic balance by removing unnecessary or excessive thrombi, thereby maintaining v...

Physicians perceptions of fixed-duration epcoritamab + lenalidomide and rituximab regimens in relapsed/refractory follicular lymphoma: Insights from the epcore NHL-2 trial

Puja Aggarwal, Robert Bone, Blaise Nwotchouang et al. Nov 03, 2025 pp. 7938-7938 10.1182/blood-2025-7938

Abstract Introduction: Follicular lymphoma (FL) is an indolent, yet incurable subtype of non-Hodgkin lymphoma characterized by frequent rela...

Response to Hetrombopag Among patients with acute and persistent primary immune thrombocytopenia: A real-world study in China

Yimei Feng, Aoxue Tan, Jia Liu et al. Nov 03, 2025 pp. 4819-4819 10.1182/blood-2025-4819

Abstract Background: Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts (PC), which increases the...

Identification of red cell distribution width as a key predictor of leukemic transformation in polycythemia vera and essential thrombocythemia: A machine learning approach involving 10,560 cases

Lior Rokach, Tamar Tadmor, Rania Abdelaziz et al. Nov 03, 2025 pp. 2021-2021 10.1182/blood-2025-2021

Abstract Background Red blood cell distribution width (RDW) is an easily accessible diagnostic test that is underutilized as a prognostic ma...

High expression of GFP on hematopoietic stem cells acts as a neoantigen triggering increased T cell-mediated clearance and reduced self-renewal

Aishwarya Krishnan, Infencia Xavier Raj, David O'Leary et al. Nov 03, 2025 pp. 4932-4932 10.1182/blood-2025-4932

Abstract Murine transplantation studies are the gold standard to assess functional potential of normal and malignant hematopoietic stem cell...

Safety and effectiveness of brentuximab vedotin in Chinese adult patients with classical Hodgkin's lymphoma: Results from a multicenter, prospective, observational, real-world study

Wei Li, Chuanxu Liu, Wenyang Huang et al. Nov 03, 2025 pp. 7135-7135 10.1182/blood-2025-7135

Abstract Introduction: Brentuximab vedotin (BV), a CD30-specific antibody-drug conjugate (ADC), is approved for the treatment of previously...

HLA mismatch-derived epitopes predict acute graft-versus-host disease risk after unrelated donor transplantation

Nicoletta Cieri, Yiren Shao, Luis Correa-Medero et al. Nov 03, 2025 pp. 4249-4249 10.1182/blood-2025-4249

Abstract Background: Complete and precise HLA matching of unrelated donors reduces the risk of complications following allogeneic hematopoie...

Downregulation of midnolin mediating non-ubiquitin protein degradation and its role in myelomagenesis.

Anna Besschetnova, Francesco Ladisa, Anaïs Schavgoulidze et al. Nov 03, 2025 pp. 2147-2147 10.1182/blood-2025-2147

Abstract To identify novel tumor suppressor genes that play critical roles in controlling myeloma cell proliferation and survival, we perfor...

Immune tolerance induction after haploidentical stem cell transplant following organ transplantation in sickle cell disease

Ali Alahmari, Saad Alghamdi, Reem Alasbali et al. Nov 03, 2025 pp. 4216-4216 10.1182/blood-2025-4216

Abstract Background: Sickle cell disease (SCD) is debilitating inherited hemoglobinopathy leading to progressive, age-dependent multi-organ...

LSD1 inhibition enhances venetoclax efficacy in Acute Myeloid Leukemia via metabolic rewiring

Kanwaldeep Singh, Emily Hartung, Anna Dvorkin-Gheva et al. Nov 03, 2025 pp. 3293-3293 10.1182/blood-2025-3293

Abstract Introduction: Acute myeloid leukemia (AML) is an aggressive hematological malignancy with poor outcomes. Venetoclax, a BCL2 inhibito...

Dnmt3a-mutant hematopoietic stem cells generate alloreactive T cells with graft vs host disease and graft vs leukemia effects

LaShanale Wallace, Mark Engelken, John Harper et al. Nov 03, 2025 pp. 7618-7618 10.1182/blood-2025-7618

Abstract Clonal hematopoiesis (CH) is an age-related phenomenon caused by expansion of a hematopoietic stem cell (HSC) clone with an acquire...

Characterization and risk factors of anticoagulation-related bleeding in patients with thrombotic antiphospholipid syndrome: An analysis using a synthetic real-world data platform

Amir Mahmoud, Kelsey Bria, Basant Eltaher et al. Nov 03, 2025 pp. 1329-1329 10.1182/blood-2025-1329

Abstract Introduction: Antiphospholipid Syndrome (APS) is a systemic autoimmune condition associated with an elevated risk of both arterial...

ASC4OPT 96-week results: Asciminib once or twice daily continues to be highly efficacious and demonstrates favorable safety in patients with chronic myeloid leukemia and suboptimal response, resistance or intolerance to two or more tyrosine kinase inhibitors

Massimo Breccia, Andreas Hochhaus, Philipp le Coutre et al. Nov 03, 2025 pp. 1993-1993 10.1182/blood-2025-1993

Abstract Introduction: The primary results of the ASC4OPT study (NCT04948333), assessing asciminib 40 mg twice daily (BID) and 80 mg once da...

Front-line consolidation with CAR-t therapy in newly diagnosed adult ph-negative b-acute lymphoblastic leukemia: Results from a prospective, phase 2 study

Runxia Gu, Shaowei Qiu, Wenbing Liu et al. Nov 03, 2025 pp. 1561-1561 10.1182/blood-2025-1561

Abstract Background: Achieving deep remission is crucial for durable responses in B-cell acute lymphoblastic leukemia (B-ALL). Our group has...

Ibrutinib plus blinatumomab in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Results of A phase 2 study

Brian Jonas, Mehrdad Abedi, Aaron Rosenberg et al. Nov 03, 2025 pp. 3356-3356 10.1182/blood-2025-3356

Abstract Background: Blinatumomab (BLIN), a CD19xCD3 bispecific T-cell engager, improves outcomes in relapsed/refractory B-cell acute lymphob...

Venetoclax plus hypomethylating agent as first- and second-line treatment in patients with AML: A single-center experience

Saša Anžej Doma, Matjaz Sever, Gaja Cvejić Vidali et al. Nov 03, 2025 pp. 6988-6988 10.1182/blood-2025-6988

Abstract Venetoclax combined with a hypomethylating agent is the standard of care for patients with newly diagnosed acute myeloid leukemia (...

Pacritinib in transplant-eligible myelofibrosis: Final analysis of the phase 2 HOVON-134 trial

Ruben Van Dijck, Bronno van der Holt, Annoek Broers et al. Nov 03, 2025 pp. 6068-6068 10.1182/blood-2025-6068

Abstract Introduction: Current EBMT/ELN-guidelines recommend pre-transplant spleen-directed management with JAK-inhibitors in symptomatic my...

First-line treatment with low-dose ruxolitinib, pirfenidone, and low-dose calcineurin inhibitors leads to significant improvement in patients with bronchiolitis obliterans syndrome after allogeneic transplantation

Zhen Li, Ruirui Gui, Juan Wang et al. Nov 03, 2025 pp. 7828-7828 10.1182/blood-2025-7828

Abstract Introduction Bronchiolitis obliterans syndrome ( BOS ) is a clinical syndrome characterized by new-onset persistent airflow limitat...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page